- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Xeris Pharmaceuticals Inc (XERS)
Xeris Pharmaceuticals Inc stock price live, this page displays NASDAQ XERS stock exchange data. View the XERS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Xeris Pharmaceuticals Inc real time stock price chart below.
What Is the Xeris Pharmaceuticals Inc Stock Price Today?
The Xeris Pharmaceuticals Inc stock price today is 7.280.
What Is the Stock Symbol for Xeris Pharmaceuticals Inc?
The stock symbol for Xeris Pharmaceuticals Inc is ""XERS.""
What Stock Exchange Does Xeris Pharmaceuticals Inc Trade On?
Xeris Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Xeris Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Xeris Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the XERS quote. (ISIN: US98422E1038)
What Is the Xeris Pharmaceuticals Inc Stock Price Today?
The Xeris Pharmaceuticals Inc stock price today is 7.280.
What Is the Stock Symbol for Xeris Pharmaceuticals Inc?
The stock symbol for Xeris Pharmaceuticals Inc is ""XERS.""
What Stock Exchange Does Xeris Pharmaceuticals Inc Trade On?
Xeris Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Xeris Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Xeris Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the XERS quote. (ISIN: US98422E1038)
NASDAQ
Currency in USD
Fair Value
An estimate of a Xeris Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.205
7.420
52 wk Range
2.480
7.610
XERS Scorecard
Full Analysis
RSI suggests the stock is in overbought territory
XERS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Xeris Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.2057.420
52 wk Range
2.4807.610
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
XERS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Xeris Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
8.167
Upside
+12.18%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Xeris Pharmaceuticals Inc Company Profile
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Xeris Pharmaceuticals Inc Earnings Call Summary for Q2/2025
- EPS of -$0.01 beat forecast of -$0.03; revenue grew 49% YoY to $71.5M, exceeding expectations by 11.85%
- Stock surged 24.04% pre-market; company raised full-year revenue guidance to $280-$290M, representing 40% YoY growth
- RECORLEV revenue increased 136%; positive adjusted EBITDA of $12.5M, a near $13M improvement YoY
- CEO emphasized strategic timing of RECORLEV; CFO highlighted strong financial position for executing strategic priorities
- Analysts inquired about Q3 Gvoke prescriptions and potential new competitors in hypercortisolism market
Last Updated: 07/08/2025, 16:46
Read Full TranscriptCompare XERS to Peers and Sector
Metrics to compare | XERS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXERSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −36.7x | 5.8x | −0.5x | |
PEG Ratio | −0.73 | 0.35 | 0.00 | |
Price/Book | −60.9x | 4.1x | 2.6x | |
Price / LTM Sales | 4.8x | 2.2x | 3.3x | |
Upside (Analyst Target) | 3.0% | 134.5% | 40.3% | |
Fair Value Upside | Unlock | 24.6% | 4.7% | Unlock |
Analyst Ratings
5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 8.167
(+12.18% Upside)
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
-0.01 / -0.03
Revenue / Forecast
71.54M / 63.96M
People Also Watch
FAQ
What Stock Exchange Does Xeris Pharmaceuticals Trade On?
Xeris Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Xeris Pharmaceuticals?
The stock symbol for Xeris Pharmaceuticals is "XERS."
What Is the Xeris Pharmaceuticals Market Cap?
As of today, Xeris Pharmaceuticals market cap is 1.18B.
What Is Xeris Pharmaceuticals's Earnings Per Share (TTM)?
The Xeris Pharmaceuticals EPS (TTM) is -0.21.
When Is the Next Xeris Pharmaceuticals Earnings Date?
Xeris Pharmaceuticals will release its next earnings report on 05 Nov 2025.
From a Technical Analysis Perspective, Is XERS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Xeris Pharmaceuticals Stock Split?
Xeris Pharmaceuticals has split 0 times.
How Many Employees Does Xeris Pharmaceuticals Have?
Xeris Pharmaceuticals has 394 employees.
What is the current trading status of Xeris Pharmaceuticals (XERS)?
As of 14 Aug 2025, Xeris Pharmaceuticals (XERS) is trading at a price of 7.28, with a previous close of 7.28. The stock has fluctuated within a day range of 7.21 to 7.42, while its 52-week range spans from 2.48 to 7.61.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.